Please login to the form below

Not currently logged in
Email:
Password:

VX-135

This page shows the latest VX-135 news and features for those working in and with pharma, biotech and healthcare.

Gilead files oral hepatitis C drug sofosbuvir in US

Gilead files oral hepatitis C drug sofosbuvir in US

However, BMS has recently signed a deal with Vertex Pharmaceuticals to partner on a clinical investigating a combination of the BMS candidate daclatasvir and Vertex' uridine nucleotide analogue VX-135.

Latest news

  • BMS and Vertex partner on oral hepatitis treatment BMS and Vertex partner on oral hepatitis treatment

    VX-135 is a uridine nucleotide analogue that, like BMS-986094, is designed to affect the NS5B polymerase to inhibit the replication the hepatitis C virus. ... GSK2336805. In addition, Vertex is planning to test the use of VX-135 along with Incivek

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

How a design mindset can lead to better medical outcomes
By adopting a design philosophy, healthcare companies can develop communications that allow healthcare professionals (HCPs) to better meet the needs of their patients. Imaginatively designed content combined with patient insights...
How does the government plan to reshape the NHS?
Oli Hudson, of Wilmington Healthcare, explores the government’s new white paper, which proposes key reforms for health and social care...
Want to give perfect client service? Tough luck, you’re human
In this article an ex-client of mine, Liz Skrbkova, and I explore the (unhelpful) pressures of trying to perfect the client-agency relationship...

Infographics